“…In addition, GABRA2 genotype has been associated with Conduct Disorder problems (Dick et al, 2006,) which have, in turn, also been linked to poor outcome (Myers et al, 1995). Thus, the potential exists for GABRA2 genotype to join the long list of clinical [e.g., severity of dependence (Bottlender and Soyka 2005), comorbid psychopathology (Ciraulo et al, 2003;Kushner et al, 2005;Pettinati et al, 1999)], psychological [e.g., self-efficacy, coping skills (Ciraulo et al, 2003;Maisto et al, 2000)], or biological [e.g., fast β EEG activity, sleep disturbance (Bauer 1994;Bauer 2001;Prichep et al, 1999;Saletu-Zyhlarz et al, 2004;Winterer et al, 1998;Brower et al, 1998;Brower et al, 2001;Clark et al, 1998;Drummond et al, 1998;Gillin et al, 1994)] variables for which a relationship to substance abuse treatment outcome has been demonstrated. If an association with GABRA2 could be demonstrated, then the field may benefit from an expansion of the theoretical framework for interpreting the causes of treatment failure.…”